Literature DB >> 25768662

Is duration of illness really influencing outcome in major psychoses?

Alfredo Carlo Altamura1, Marta Serati, Massimiliano Buoli.   

Abstract

BACKGROUND: An increasing number of studies identifies the duration of illness (DI) as an important predictor of outcome in patients affected by major psychoses (MP). The aim of the present paper was to revise medical literature about DI and its effects on MP, focusing in particular on the relationship between DI and outcome with particular reference to treatment response, suicidal risk, cognitive impairment and social functioning.
METHODS: A search in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while papers considering other variables such as duration of untreated episode/illness were excluded. MP included the diagnoses of schizophrenia, bipolar disorder and major depressive disorder.
RESULTS: Available data show that DI influences treatment response, suicidal risk and loss of social functioning in schizophrenic patients, while results are more controversial with regard to cognitive impairment. In bipolar disorder, a long DI has been associated with less treatment response, more suicidal risk and cognitive impairment, but more data are needed to draw definitive conclusions. Finally, studies, regarding DI of illness and its predictive value of outcome in major depressive disorder show contradictory results.
CONCLUSIONS: DI appears a negative outcome factor particularly for schizophrenia, while with regard to mood disorders, more data are needed to draw definitive sound conclusions.

Entities:  

Keywords:  Duration of illness (DI); Major psychoses (MP); Outcome

Mesh:

Year:  2015        PMID: 25768662     DOI: 10.3109/08039488.2014.990919

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  13 in total

1.  Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study.

Authors:  Sheng-Yu Lee; Tzu-Yun Wang; Shiou-Lan Chen; Yun-Hsuan Chang; Po-See Chen; San-Yuan Huang; Nian-Sheng Tzeng; Liang-Jen Wang; I Hui Lee; Kao Ching Chen; Yen Kuang Yang; Jau-Shyong Hong; Ru-Band Lu
Journal:  Alcohol Clin Exp Res       Date:  2018-05-17       Impact factor: 3.455

2.  The Important Role of Motivation and Pleasure Deficits on Social Functioning in Patients With Schizophrenia: A Network Analysis.

Authors:  Hui-Xin Hu; Wilson Y S Lau; Eugenia P Y Ma; Karen S Y Hung; Si-Yu Chen; Kin-Shing Cheng; Eric F C Cheung; Simon S Y Lui; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

3.  Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.

Authors:  Luis Gutiérrez-Rojas; Sergio Sánchez-Alonso; Marta García Dorado; Paola M López Rengel
Journal:  CNS Drugs       Date:  2022-04-23       Impact factor: 6.497

4.  Quetiapine-Induced Hypomania and its Association with Quetiapine/Norquetiapine Plasma Concentrations: A Case Series of Bipolar Type 2 Patients.

Authors:  C Rovera; C M Esposito; V Ciappolino; D Cattaneo; S Baldelli; E Clementi; A C Altamura; M Buoli
Journal:  Drug Saf Case Rep       Date:  2017-10-23

5.  Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Authors:  Martin A Katzman; Andrew A Nierenberg; Dalia B Wajsbrot; Ellen Meier; Rita Prieto; Elizabeth Pappadopulos; Joan Mackell; Matthieu Boucher
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

6.  Cognitive correlates of neuroimaging abnormalities in the onset of schizophrenia: A case report.

Authors:  Silvia Grassi; Giulia Orsenigo; Marta Serati; Elisabetta Caletti; Alfredo Carlo Altamura; Massimiliano Buoli
Journal:  World J Psychiatry       Date:  2017-06-22

7.  Gene Expression Profiles Associated with Brain Aging are Altered in Schizophrenia.

Authors:  Sarven Sabunciyan
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

8.  What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors.

Authors:  Dominic Oliver; Thomas J Reilly; Ottone Baccaredda Boy; Natalia Petros; Cathy Davies; Stefan Borgwardt; Philip McGuire; Paolo Fusar-Poli
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

Review 9.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

10.  Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies.

Authors:  Dominic Oliver; Cathy Davies; Georgia Crossland; Steffiany Lim; George Gifford; Philip McGuire; Paolo Fusar-Poli
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.